

EXCEPTIONS CRITERIA

GONADOTROPIN RELEASING HORMONE AGONISTS

PREFERRED PRODUCT: ELIGARD

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the gonadotropin releasing hormone agonist products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Gonadotropin releasing hormone agonists

	Product(s)
Preferred*	<ul style="list-style-type: none">• Eligard (leuprolide acetate)
Targeted	<ul style="list-style-type: none">• Camcevi (leuprolide mesylate)• Lupron Depot (leuprolide acetate for depot suspension)• Trelstar (triptorelin)• Zoladex (goserelin acetate)

*Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

II. EXCEPTION CRITERIA

This program applies to members requesting treatment for prostate cancer.

Coverage for a targeted product is provided when either of the following criteria is met:

- A. Member has received treatment with a targeted product in the past 365 days.
- B. Member has a documented hypersensitivity to the preferred product.

REFERENCES

1. Camcevi [package insert]. Durham, NC: Accord BioPharma Inc.; May 2021.
2. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; April 2019.
3. Lupron Depot [package insert]. North Chicago, IL: AbbVie Inc.; April 2022.
4. Trelstar [package insert]. Ewing, NJ: Verity Pharmaceuticals, Inc.; March 2023.
5. Zoladex [package insert]. Deerfield, IL: TerSera Therapeutics LLC; December 2020.

Specialty Exceptions GnRH-Prostate MED B-MED B BF-MED B ABF 4257-D P2024_v2.docx © 2024 Clover Health. All rights reserved.

This document contains confidential and proprietary information of Clover Health and cannot be reproduced, distributed or printed without written permission from Clover Health. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with Clover Health.